Esperion's Nexlizet (bempedoic acid and ezetimibe) Tablet Receives the US FDA's Approval as LDL-Cholesterol Lowering Medicine
Shots:
- The approval is based on P-III trial Fixed Combination Drug Product LDL-C Lowering program- involves assessing of Nexlizet vs PBO when added on to maximally tolerated statins
- The study resulted in well-tolerated data and lowered LDL-C by 38%- when added on to maximally tolerated statins. Also- the results are published in The European Journal of Preventative Cardiology
- Nexlizet is an oral qd- non-statin LDL-cholesterol lowering medicine approved by the US FDA on Feb 21- 2020 and will be available in Jul- 2020. Nexletol (bempedoic acid) is a novel ATP Citrate Lyase inhibitor involves lowering of LDL-C by cholesterol biosynthesis and up-regulating the LDL receptors- will be available from Mar 30- 2020
Click here to read full press release/ article | Ref: GlobNewswire | Image: Signbox
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com